Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30124891 | 1.00 | SMN1; SMN2 (0.58) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| SCHEMBL24719656 | 0.95 | SMN1; SMN2 (0.64) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| SCHEMBL28305720 | 0.90 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| Hydrogen Sulfide SCHEMBL27704711 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| Acetic Acid SCHEMBL28306932 | 0.88 | SMN1; SMN2 (0.64) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| Phenol SCHEMBL28913831 | 0.87 | MAPT (0.61) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| Fluoride SCHEMBL27907088 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| SCHEMBL30124354 | 0.84 | SMN1; SMN2 (0.55) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| SCHEMBL171741 | 0.84 | L3MBTL1 (0.83) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 | |
| SCHEMBL28897775 | 0.83 | SMN1; SMN2 (0.62) | SMN1; SMN2L3MBTL1HTTNAPRTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. | 2024-07-04 | — | — | US | disclosed |
| WO-2024123999-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20230025178-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-01-26 | — | — | US | disclosed |
| WO-2022261204-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025178-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | SMN1; SMN2 4326/4885L3MBTL1 2447/4885HTT 1993/4885 |
| US-20240217952-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | BRDT, BET1, BRD4 | SMN1; SMN2 4139/4885L3MBTL1 728/4885HTT 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.